Neuphoria Therapeutics Inc Financials
This page shows Neuphoria Therapeutics Inc (NEUP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Neuphoria Therapeutics Inc has an operating margin of -7.2%, meaning the company retains $-7 of operating profit per $100 of revenue. This below-average margin results in a low score of 6/100, suggesting thin profitability after operating expenses.
Neuphoria Therapeutics Inc carries a low D/E ratio of 0.50, meaning only $0.50 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 92/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.56, Neuphoria Therapeutics Inc holds $3.56 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 69/100.
Neuphoria Therapeutics Inc generates a -2.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 6/100. This is up from -88.6% the prior year.
Neuphoria Therapeutics Inc passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Neuphoria Therapeutics Inc generates $-0.19 in operating cash flow ($77K OCF vs -$400K net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Key Financial Metrics
Earnings & Revenue
Neuphoria Therapeutics Inc generated $15.6M in revenue in fiscal year 2025.
Neuphoria Therapeutics Inc's EBITDA was -$466K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 97.3% from the prior year.
Neuphoria Therapeutics Inc reported -$400K in net income in fiscal year 2025. This represents an increase of 97.4% from the prior year.
Neuphoria Therapeutics Inc earned $-0.23 per diluted share (EPS) in fiscal year 2025. This represents an increase of 98.8% from the prior year.
Cash & Balance Sheet
Neuphoria Therapeutics Inc held $14.2M in cash against $0 in long-term debt as of fiscal year 2025.
Neuphoria Therapeutics Inc had 2M shares outstanding in fiscal year 2025. This represents an increase of 70.3% from the prior year.
Margins & Returns
Neuphoria Therapeutics Inc's operating margin was -7.2% in fiscal year 2025, reflecting core business profitability.
Neuphoria Therapeutics Inc's net profit margin was -2.6% in fiscal year 2025, showing the share of revenue converted to profit.
Neuphoria Therapeutics Inc's ROE was -2.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 86.5 percentage points from the prior year.
Capital Allocation
Neuphoria Therapeutics Inc invested $9.0M in research and development in fiscal year 2025. This represents a decrease of 4.4% from the prior year.
NEUP Income Statement
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $663K | N/A | N/A | N/A | $15.0M+2163.4% | $663K | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $698K0.0% | $698K-81.6% | $3.8M | N/A | $1.6M-7.0% | $1.7M-8.6% | $1.9M | N/A |
| SG&A Expenses | $2.1M0.0% | $2.1M+13.9% | $1.9M | N/A | $1.4M-46.5% | $2.6M+57.7% | $1.7M | N/A |
| Operating Income | $4.1M+200.0% | -$4.1M+28.2% | -$5.7M | N/A | $12.0M+423.4% | -$3.7M-3.8% | -$3.6M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $35K+200.0% | -$35K0.0% | -$35K | N/A | -$81K-799.3% | $12K+108.8% | -$132K | N/A |
| Net Income | $1.9M0.0% | $1.9M+118.8% | -$9.9M | N/A | $11.3M+679.5% | -$1.9M-141.5% | -$805K | N/A |
| EPS (Diluted) | $0.77+200.0% | $-0.77+82.5% | $-4.41 | N/A | $6.55+465.9% | $-1.79 | $-0.62 | N/A |
NEUP Balance Sheet
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $36.6M0.0% | $36.6M+33.8% | $27.3M-4.4% | $28.6M-6.9% | $30.7M+69.0% | $18.2M-20.7% | $22.9M-17.1% | $27.6M |
| Current Assets | $23.4M0.0% | $23.4M+67.6% | $14.0M-7.2% | $15.0M-12.0% | $17.1M+288.5% | $4.4M-47.8% | $8.4M-36.1% | $13.2M |
| Cash & Equivalents | $22.2M0.0% | $22.2M+62.4% | $13.6M-3.9% | $14.2M-16.6% | $17.0M+292.3% | $4.3M-46.2% | $8.1M-35.9% | $12.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $1.1M0.0% | $1.1M+63034.7% | $2K-85.3% | $12K-51.4% | $25K-30.8% | $36K-69.3% | $116K-8.6% | $127K |
| Goodwill | $8.7M0.0% | $8.7M+0.7% | $8.7M+0.4% | $8.6M+2.2% | $8.5M+0.5% | $8.4M-5.6% | $8.9M+2.5% | $8.7M |
| Total Liabilities | $6.9M0.0% | $6.9M-53.5% | $14.8M+54.7% | $9.6M+103.3% | $4.7M+6.7% | $4.4M-24.4% | $5.8M-42.4% | $10.2M |
| Current Liabilities | $2.6M0.0% | $2.6M-49.5% | $5.1M+21.4% | $4.2M+171.9% | $1.6M-27.3% | $2.1M-16.4% | $2.6M-33.4% | $3.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $29.7M0.0% | $29.7M+137.4% | $12.5M-34.2% | $19.0M-26.9% | $26.0M+89.1% | $13.7M-19.5% | $17.1M-2.4% | $17.5M |
| Retained Earnings | $186.4M+200.0% | -$186.4M+1.0% | -$188.3M-5.6% | -$178.3M-5.2% | -$169.5M+6.2% | -$180.7M-1.1% | -$178.8M-0.5% | -$178.0M |
NEUP Cash Flow Statement
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $17.6M+373.6% | -$6.4M-69.6% | -$3.8M-5.8% | -$3.6M-131.3% | $11.5M+441.1% | -$3.4M+24.2% | -$4.4M-47.2% | -$3.0M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $14.0M-4.8% | $14.7M+350.6% | $3.3M+361.7% | $705K-39.4% | $1.2M+1142.0% | -$112K+50.9% | -$227K-103.2% | $7.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NEUP Financial Ratios
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | 612.8% | N/A | N/A | N/A | 79.8%+638.7pp | -558.8% | N/A | N/A |
| Net Margin | 281.3% | N/A | N/A | N/A | 75.1%+368.3pp | -293.2% | N/A | N/A |
| Return on Equity | 6.3%0.0pp | 6.3%+85.5pp | -79.2% | N/A | 43.3%+57.5pp | -14.1%-9.4pp | -4.7% | N/A |
| Return on Assets | 5.1%0.0pp | 5.1%+41.3pp | -36.2% | N/A | 36.7%+47.4pp | -10.7%-7.2pp | -3.5% | N/A |
| Current Ratio | 9.040.0 | 9.04+6.3 | 2.72-0.8 | 3.56-7.4 | 11.01+8.9 | 2.06-1.2 | 3.30-0.1 | 3.45 |
| Debt-to-Equity | 0.230.0 | 0.23-1.0 | 1.19+0.7 | 0.50+0.3 | 0.18-0.1 | 0.32-0.0 | 0.34-0.2 | 0.58 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Neuphoria Therapeutics Inc's annual revenue?
Neuphoria Therapeutics Inc (NEUP) reported $15.6M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Neuphoria Therapeutics Inc profitable?
No, Neuphoria Therapeutics Inc (NEUP) reported a net income of -$400K in fiscal year 2025, with a net profit margin of -2.6%.
What is Neuphoria Therapeutics Inc's EBITDA?
Neuphoria Therapeutics Inc (NEUP) had EBITDA of -$466K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Neuphoria Therapeutics Inc's operating margin?
Neuphoria Therapeutics Inc (NEUP) had an operating margin of -7.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Neuphoria Therapeutics Inc's net profit margin?
Neuphoria Therapeutics Inc (NEUP) had a net profit margin of -2.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Neuphoria Therapeutics Inc's return on equity (ROE)?
Neuphoria Therapeutics Inc (NEUP) has a return on equity of -2.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Neuphoria Therapeutics Inc's operating cash flow?
Neuphoria Therapeutics Inc (NEUP) generated $77K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Neuphoria Therapeutics Inc's total assets?
Neuphoria Therapeutics Inc (NEUP) had $28.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Neuphoria Therapeutics Inc spend on research and development?
Neuphoria Therapeutics Inc (NEUP) invested $9.0M in research and development during fiscal year 2025.
What is Neuphoria Therapeutics Inc's current ratio?
Neuphoria Therapeutics Inc (NEUP) had a current ratio of 3.56 as of fiscal year 2025, which is generally considered healthy.
What is Neuphoria Therapeutics Inc's debt-to-equity ratio?
Neuphoria Therapeutics Inc (NEUP) had a debt-to-equity ratio of 0.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Neuphoria Therapeutics Inc's return on assets (ROA)?
Neuphoria Therapeutics Inc (NEUP) had a return on assets of -1.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Neuphoria Therapeutics Inc's Piotroski F-Score?
Neuphoria Therapeutics Inc (NEUP) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Neuphoria Therapeutics Inc's earnings high quality?
Neuphoria Therapeutics Inc (NEUP) has an earnings quality ratio of -0.19x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Neuphoria Therapeutics Inc?
Neuphoria Therapeutics Inc (NEUP) scores 43 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.